Most reports on chronic myeloid leukaemia (CML) treatment with tyrosine kinase inhibitors
(TKIs) focus on efficacy, particularly on molecular response and outcome. In contrast …

Vascular safety is an emerging issue in patients with chronic myeloid leukemia (CML)
treated with tyrosine kinase inhibitors (TKIs). Whereas imatinib exhibits a well-documented …

Abstract In the phase 3 Evaluating Nilotinib Efficacy and Safety in Clinical Trials–Newly
Diagnosed Patients (ENESTnd) study, nilotinib resulted in earlier and higher response rates …

This analysis from the multicenter, open-label, phase 3 BFORE trial reports efficacy and
safety of bosutinib in patients with newly diagnosed chronic phase (CP) chronic myeloid …

Background The present review is part of the European Society of Clinical Microbiology and
Infectious Diseases (ESCMID) Study Group for Infections in Compromised Hosts (ESGICH) …

The past 2 decades have seen a revolution in our approach to therapeutic
immunosuppression. We have moved from relying on broadly active traditional medications …

Importance A phase 3 trial with ponatinib in patients with chronic myeloid leukemia (CML)
was interrupted due to an important increase of vascular occlusive events. A similar risk was …

Imatinib, the first tyrosine kinase inhibitor (TKI) for the treatment of chronic myeloid leukemia
(CML), improves overall survival (OS), but the introduction of newer TKIs requires the …

The development of BCR:: ABL1-targeting tyrosine kinase inhibitors (TKIs) has improved the
prognosis of patients with chronic myeloid leukemia (CML). Although there are some …

Bosutinib is approved for newly diagnosed Philadelphia chromosome-positive (Ph+) chronic
phase (CP) chronic myeloid leukemia (CML) and for Ph+ CP, accelerated (AP), or blast (BP) …